CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma : A case report
Copyright: © Wang et al..
Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has changed the typical outcomes of relapsed/refractory B-cell leukemia and lymphoma. However, treatment effectiveness for patients with relapsed/refractory B-cell non-Hodgkin lymphoma has been less satisfactory compared with patients with B-cell acute lymphoblastic leukemia. The present study described a case of refractory follicular lymphoma. A high expression of programmed cell death 1 (PD-1) was measured on CD3+ T cells (80.90%) in peripheral blood samples obtained from the patient enrolled in this study, indicating that treatment with autologous CAR-T 19 cell therapy may not be successful. Therefore, a therapy regimen consisting of CAR-T 19 cells in combination with a reduced dose of nivolumab (1.5 mg/kg) for PD-1 blockade was used. A low dose of PD-1 blockade therapy was used to reduce the adverse effects associated with the combination of a PD-1 inhibitor and CAR-T 19 cells. This salvage therapy resulted in remission that lasted for >10 months.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Oncology letters - 18(2019), 5 vom: 15. Nov., Seite 4415-4420 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Jia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chimeric antigen receptor |
|---|
| Anmerkungen: |
Date Revised 30.09.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3892/ol.2019.10783 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM302186387 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM302186387 | ||
| 003 | DE-627 | ||
| 005 | 20231225110206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/ol.2019.10783 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1007.xml |
| 035 | |a (DE-627)NLM302186387 | ||
| 035 | |a (NLM)31611950 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Jia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CAR-T 19 combined with reduced-dose PD-1 blockade therapy for treatment of refractory follicular lymphoma |b A case report |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © Wang et al. | ||
| 520 | |a Anti-CD19 chimeric antigen receptor T cell (CAR-T) therapy has changed the typical outcomes of relapsed/refractory B-cell leukemia and lymphoma. However, treatment effectiveness for patients with relapsed/refractory B-cell non-Hodgkin lymphoma has been less satisfactory compared with patients with B-cell acute lymphoblastic leukemia. The present study described a case of refractory follicular lymphoma. A high expression of programmed cell death 1 (PD-1) was measured on CD3+ T cells (80.90%) in peripheral blood samples obtained from the patient enrolled in this study, indicating that treatment with autologous CAR-T 19 cell therapy may not be successful. Therefore, a therapy regimen consisting of CAR-T 19 cells in combination with a reduced dose of nivolumab (1.5 mg/kg) for PD-1 blockade was used. A low dose of PD-1 blockade therapy was used to reduce the adverse effects associated with the combination of a PD-1 inhibitor and CAR-T 19 cells. This salvage therapy resulted in remission that lasted for >10 months | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chimeric antigen receptor | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a lymphoma | |
| 650 | 4 | |a programmed cell death 1 blockade | |
| 650 | 4 | |a programmed cell death 1 inhibitor | |
| 700 | 1 | |a Deng, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Yan-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Hai-Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Juan-Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yu-Ming |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology letters |d 2010 |g 18(2019), 5 vom: 15. Nov., Seite 4415-4420 |w (DE-627)NLM201171317 |x 1792-1082 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2019 |g number:5 |g day:15 |g month:11 |g pages:4415-4420 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/ol.2019.10783 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2019 |e 5 |b 15 |c 11 |h 4415-4420 | ||